Diagnosis and treatment for familial gastric cancer

Yoshihiko Maehara, Hideo Baba, Shinya Oda, Yoshihiro Kakeji, Yasunori Emi, Keizo Sugimachi

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The criteria for familial gastric cancer are as follows: 1) there should be at least 3 relatives with gastric cancer, 2) one should be a first-degree relative of the other 2, 3) at least 2 successive generations should be affected, 4) at least 1 should be diagnosed before age 50, and 5) other familial tumors should be excluded. There are two types of familial gastric cancer, diffuse type and intestinal type, of which the genetic background seems to be differ. In 1998, an autosomal dominant syndrome of diffuse gastric cancer was reported with germline mutations in the E-cadherin gene and has been identified in approximately 14 families and 50 individuals worldwide. In addition, an inherited mutation in mismatch repair (MMR) genes was found in hereditary non-polyposis colorectal cancer (HNPCC) in 1993. Since there is high frequency microsatellite instability found in familial gastric cancer patients, vigorous efforts have been made to find abnormalities in MMR genes of familial gastric cancer patients. However, to date, there has been little progress in detecting MMR gene mutations in familial gastric cancer patients. It is clinically most important to obtain a detailed family history to identify familial gastric cancer patients. At present, prophylactic total gastrectomy for familial gastric cancer is under careful consideration.

Original languageEnglish
Pages (from-to)523-531
Number of pages9
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume29
Issue number4
Publication statusPublished - Jan 1 2002

Fingerprint

Stomach Neoplasms
DNA Mismatch Repair
Therapeutics
Genes
Microsatellite Instability
Mutation
Germ-Line Mutation
Cadherins
Gastrectomy
Colorectal Neoplasms
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Maehara, Y., Baba, H., Oda, S., Kakeji, Y., Emi, Y., & Sugimachi, K. (2002). Diagnosis and treatment for familial gastric cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 29(4), 523-531.

Diagnosis and treatment for familial gastric cancer. / Maehara, Yoshihiko; Baba, Hideo; Oda, Shinya; Kakeji, Yoshihiro; Emi, Yasunori; Sugimachi, Keizo.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 29, No. 4, 01.01.2002, p. 523-531.

Research output: Contribution to journalReview article

Maehara, Y, Baba, H, Oda, S, Kakeji, Y, Emi, Y & Sugimachi, K 2002, 'Diagnosis and treatment for familial gastric cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 29, no. 4, pp. 523-531.
Maehara Y, Baba H, Oda S, Kakeji Y, Emi Y, Sugimachi K. Diagnosis and treatment for familial gastric cancer. Gan to kagaku ryoho. Cancer & chemotherapy. 2002 Jan 1;29(4):523-531.
Maehara, Yoshihiko ; Baba, Hideo ; Oda, Shinya ; Kakeji, Yoshihiro ; Emi, Yasunori ; Sugimachi, Keizo. / Diagnosis and treatment for familial gastric cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2002 ; Vol. 29, No. 4. pp. 523-531.
@article{9e688ee2d2dc4f0980d4a66b66a19df7,
title = "Diagnosis and treatment for familial gastric cancer",
abstract = "The criteria for familial gastric cancer are as follows: 1) there should be at least 3 relatives with gastric cancer, 2) one should be a first-degree relative of the other 2, 3) at least 2 successive generations should be affected, 4) at least 1 should be diagnosed before age 50, and 5) other familial tumors should be excluded. There are two types of familial gastric cancer, diffuse type and intestinal type, of which the genetic background seems to be differ. In 1998, an autosomal dominant syndrome of diffuse gastric cancer was reported with germline mutations in the E-cadherin gene and has been identified in approximately 14 families and 50 individuals worldwide. In addition, an inherited mutation in mismatch repair (MMR) genes was found in hereditary non-polyposis colorectal cancer (HNPCC) in 1993. Since there is high frequency microsatellite instability found in familial gastric cancer patients, vigorous efforts have been made to find abnormalities in MMR genes of familial gastric cancer patients. However, to date, there has been little progress in detecting MMR gene mutations in familial gastric cancer patients. It is clinically most important to obtain a detailed family history to identify familial gastric cancer patients. At present, prophylactic total gastrectomy for familial gastric cancer is under careful consideration.",
author = "Yoshihiko Maehara and Hideo Baba and Shinya Oda and Yoshihiro Kakeji and Yasunori Emi and Keizo Sugimachi",
year = "2002",
month = "1",
day = "1",
language = "English",
volume = "29",
pages = "523--531",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "4",

}

TY - JOUR

T1 - Diagnosis and treatment for familial gastric cancer

AU - Maehara, Yoshihiko

AU - Baba, Hideo

AU - Oda, Shinya

AU - Kakeji, Yoshihiro

AU - Emi, Yasunori

AU - Sugimachi, Keizo

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The criteria for familial gastric cancer are as follows: 1) there should be at least 3 relatives with gastric cancer, 2) one should be a first-degree relative of the other 2, 3) at least 2 successive generations should be affected, 4) at least 1 should be diagnosed before age 50, and 5) other familial tumors should be excluded. There are two types of familial gastric cancer, diffuse type and intestinal type, of which the genetic background seems to be differ. In 1998, an autosomal dominant syndrome of diffuse gastric cancer was reported with germline mutations in the E-cadherin gene and has been identified in approximately 14 families and 50 individuals worldwide. In addition, an inherited mutation in mismatch repair (MMR) genes was found in hereditary non-polyposis colorectal cancer (HNPCC) in 1993. Since there is high frequency microsatellite instability found in familial gastric cancer patients, vigorous efforts have been made to find abnormalities in MMR genes of familial gastric cancer patients. However, to date, there has been little progress in detecting MMR gene mutations in familial gastric cancer patients. It is clinically most important to obtain a detailed family history to identify familial gastric cancer patients. At present, prophylactic total gastrectomy for familial gastric cancer is under careful consideration.

AB - The criteria for familial gastric cancer are as follows: 1) there should be at least 3 relatives with gastric cancer, 2) one should be a first-degree relative of the other 2, 3) at least 2 successive generations should be affected, 4) at least 1 should be diagnosed before age 50, and 5) other familial tumors should be excluded. There are two types of familial gastric cancer, diffuse type and intestinal type, of which the genetic background seems to be differ. In 1998, an autosomal dominant syndrome of diffuse gastric cancer was reported with germline mutations in the E-cadherin gene and has been identified in approximately 14 families and 50 individuals worldwide. In addition, an inherited mutation in mismatch repair (MMR) genes was found in hereditary non-polyposis colorectal cancer (HNPCC) in 1993. Since there is high frequency microsatellite instability found in familial gastric cancer patients, vigorous efforts have been made to find abnormalities in MMR genes of familial gastric cancer patients. However, to date, there has been little progress in detecting MMR gene mutations in familial gastric cancer patients. It is clinically most important to obtain a detailed family history to identify familial gastric cancer patients. At present, prophylactic total gastrectomy for familial gastric cancer is under careful consideration.

UR - http://www.scopus.com/inward/record.url?scp=0036551215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036551215&partnerID=8YFLogxK

M3 - Review article

C2 - 11977535

AN - SCOPUS:0036551215

VL - 29

SP - 523

EP - 531

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 4

ER -